REMAP-CAP

We are delighted to share with you that REMAP-CAP has been selected by the NIHR as the platform trial to evaluate therapeutic interventions for influenza! It is great that they have recognised all the fantastic work you have helped achieve with COVID-19 and now we can continue to use our exciting trial design to study flu in a wider population. 


Sites open

Global: 332  UK: 143

Patients randomised (all)

Global: 11,519 UK: 5,666

Patients randomised (COVID-19)

Global: 9,945 UK: 5,539

What is this study about?

REMAP-CAP is an international (15 countries) adaptive platform trial in community acquired pneumonia, that was specifically designed to be employed in a pandemic to evaluate multiple interventions simultaneously in critically ill patients. In addition to recruiting patients with community acquired pneumonia who have been admitted to critical care, we are also recruiting patients with COVID-19 to understand optimal treatment strategies.

The trial is modular so that new domains (groups of similar treatment options) can be added over time.

Community Acquired Pneumonia treatment domains:

• Antivirals (influenza) Three interventions: (1) No antiviral for influenza; (2) Oseltamivir (5 days); (3) Oseltamivir (10 days)
• Corticosteroids Three interventions: (1) No steroids; (2) Steroids for 7 days (3) Steroids if shock present

• Antibiotics Five interventions: (1) Ceftriaxone + Macrolide; (2) Moxifloxacin or Levofloxacin; (3) Piperacillin-tazobactam + Macrolide (4) Ceftaroline + Macrolide (5) Amoxicillin-clavulanate + Macrolide

• Macrolide duration Two interventions: (1) Standard course (3-5 days); (2) Extended course (14 days)

• Cysteamine Two interventions: (1) No cysteamine; (2) Cysteamine